Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Buprenorphine (Buvidal®) is recommended as an option for use within NHS Wales for the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
|||
|
|||
Medicine details |
|||
| Medicine name | buprenorphine (Buvidal®) | ||
| Formulation | 8 mg, 16 mg, 24 mg, 32 mg, 64 mg, 96 mg and 128 mg solution for injection | ||
| Reference number | 3977 | ||
| Indication | Treatment of opioid dependence in adults and adolescents aged 16 years or over within a framework of medical, social and psychological treatment |
||
| Company | Camurus AB | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1119 | ||
| NMG meeting date | 12/06/2019 | ||
| AWMSG meeting date | 11/09/2019 | ||
| Date of issue | 18/09/2019 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||
| Scrutiny Panel meeting date | useMuraDefault | ||
| LOWMAG meeting date | useMuraDefault | ||
| OWMAG meeting date | useMuraDefault | ||